OpGen Announces Data from Prospective Randomized Controlled Multicenter Clinical Study Using the Unyvero HPN Panel for Hospitalized Patients with Suspicion of Pneumonia
15 sept. 2021 07h30 HE
|
OpGen, Inc.
- Unyvero reduced the use of inappropriate antibiotic therapy by 45.1% - Unyvero shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.54% - 3...
OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update
12 août 2021 16h15 HE
|
OpGen, Inc.
Total Revenue for Q2 2021 was approximately $0.8 millionCash as of June 30, 2021 was approximately $31.2 million, up significantly from the $13.4 million at year-end 2020 Conference call to be...
OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting
04 août 2021 16h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2021 on August 12th at 4:30 p.m. Eastern Time
04 août 2021 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program
03 août 2021 07h30 HE
|
OpGen, Inc.
- OpGen subsidiary Curetis and its instrument development partner have completed assembly of 10 final pre-series release A30 RQ analyzers - Unyvero A30 RQ instruments are now readily available for...
OpGen Announces Partial Adjournment of Annual Meeting
07 juil. 2021 16h30 HE
|
OpGen, Inc.
Adjournment solely with respect to Proposal 2 (increase in authorized shares)Company and Board to Explore Alternative Options ROCKVILLE, Md., July 07, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc....
OpGen Announces Prospective Clinical Data from Unyvero LRT BAL and Acuitas AMR Gene Panel for Isolates Data Presented at World Microbe Forum
30 juin 2021 07h30 HE
|
OpGen, Inc.
- Unyvero studies demonstrated potential for therapy adjustment in 42% to 53% of patients with results available 1 to 2 days faster - Acuitas AMR Gene Panel for Isolates (RUO) studies demonstrate...
OpGen Group Company Ares Genetics Presents R&D Pipeline Updates
28 juin 2021 07h30 HE
|
OpGen, Inc.
Preliminary data demonstrates robust performance on nanopore sequencingAccuracy of 100% for pathogen identification and up to 97% for AMR markers and up to 100% on predicting AST ROCKVILLE, Md.,...
OpGen Announces Partial Adjournment of Annual Meeting for Proposal 2 with All Other Proposals Passed
09 juin 2021 16h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., June 09, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...
OpGen Group Company Ares Genetics Presents at AWS and Twist Bioscience Webinars
09 juin 2021 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., June 09, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...